CorMedix (NASDAQ:CRMD) Announces Earnings Results, Beats Estimates By $0.05 EPS

Posted by on Aug 15th, 2026

CorMedix (NASDAQ:CRMD – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.05, FiscalAI reports. The firm had revenue of $101.93 million during the quarter, compared to analysts’ expectations of $96.04 million. CorMedix had a return on equity of 41.90% and a net margin of 40.49%.

Here are the key takeaways from CorMedix’s conference call:

  • Second-quarter revenue rose to $101.9 million, including $66.1 million from DefenCath and $35.8 million from the acquired Melinta portfolio; adjusted EBITDA increased to $58.7 million.
  • CorMedix signed a multi-year DefenCath supply agreement with its fifth major U.S. dialysis provider. The LDO will begin a pilot involving several hundred clinics in the third quarter, with potential expansion in 2027.
  • The company reaffirmed 2026 revenue guidance of $325 million to $345 million and raised adjusted EBITDA guidance to $125 million to $140 million, while noting that post-TDAPA ordering patterns remain an uncertainty.
  • CorMedix expects Mundipharma to submit an sNDA for REZZAYO as prophylaxis against invasive fungal disease in the third quarter, potentially leading to FDA action in the first half of 2027 following positive Phase III results.
  • DefenCath volumes have stabilized among larger dialysis providers but experienced some attrition among smaller accounts after TDAPA expiration; meaningful volume growth may depend on the new LDO pilot and Medicare Advantage contracting, which is not included in 2026 guidance.

CorMedix Price Performance

Shares of NASDAQ:CRMD opened at $7.54 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.74 and a current ratio of 2.97. The business’s fifty day moving average price is $8.14 and its two-hundred day moving average price is $7.65. The stock has a market cap of $591.51 million, a PE ratio of 3.52 and a beta of 1.50. CorMedix has a one year low of $6.13 and a one year high of $14.96.

Institutional Trading of CorMedix

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in CorMedix by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock worth $222,000 after purchasing an additional 1,631 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of CorMedix by 17.1% during the 2nd quarter. Legal & General Group Plc now owns 62,620 shares of the company’s stock worth $771,000 after purchasing an additional 9,155 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of CorMedix by 13.9% during the second quarter. Rhumbline Advisers now owns 92,905 shares of the company’s stock worth $1,145,000 after buying an additional 11,340 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of CorMedix by 22.2% during the second quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after buying an additional 1,190 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of CorMedix in the second quarter valued at approximately $199,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Royal Bank Of Canada increased their price target on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Friday. Leerink Partners lifted their price target on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of CorMedix in a report on Monday, April 27th. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Finally, Needham & Company LLC upped their target price on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, April 27th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

View Our Latest Report on CorMedix

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

  • Positive Sentiment: Q2 results exceeded expectations: CorMedix reported earnings of $0.29 per share versus the $0.28 consensus estimate and revenue of $101.9 million, ahead of expectations near $96.0 million. Net income was $26.0 million and adjusted EBITDA was $58.7 million. CorMedix Second-Quarter Results
  • Positive Sentiment: DefenCath and Melinta drove growth: Management cited solid DefenCath utilization and contributions from the Melinta portfolio as key factors behind the revenue beat, supporting the company’s commercial growth story. CRMD Q2 Earnings and Sales Beat
  • Positive Sentiment: Profitability outlook improved: CorMedix maintained its fiscal 2026 revenue guidance of $325 million to $345 million, approximately in line with the $334.7 million analyst consensus, while raising its adjusted EBITDA guidance. The company also expects a supplemental filing for its fungal disease treatment by the third quarter, adding a potential pipeline catalyst. CorMedix Supplemental Filing Outlook
  • Positive Sentiment: Analyst support strengthened: Royal Bank of Canada raised its price target from $13 to $14 and assigned an “outperform” rating. Other brokerages collectively maintain a “moderate buy” recommendation. RBC Price Target Update
  • Neutral Sentiment: Guidance remains broadly aligned with expectations: Although the revenue outlook was maintained rather than raised, the higher EBITDA guidance indicates improving operating leverage and margins. Investors will likely focus on DefenCath adoption and execution against the second-half forecast.

About CorMedix

(Get Free Report)

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.

Read More

Earnings History for CorMedix (NASDAQ:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.